NCT05538624 - A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

April 10, 2024

Conditions

Neoplasm, OvarianFallopian Tube CancerPrimary Peritoneal Cavity CancerAdenocarcinoma OvarySerous Adenocarcinoma of OvarySerous Adenocarcinoma of Primary PeritoneumPrimary Peritoneal CarcinomaHigh Grade Serous Adenocarcinoma

Interventions

DRUG

AVB-001 (Dose Escalation Phase)

One of four ascending doses of AVB-001 planned for IP, single dose administration in each dose level cohort of the Dose Escalation Phase (Part 1).

DRUG

AVB-001 (Dose Expansion Phase)

The MTD/RP2D as determined in the Dose Escalation Phase will be further evaluated in the Dose Expansion Phase.

Trial Locations (5)

15213

UPMC Magee-Womens Hospital, Pittsburgh

20892

National Cancer Institute, Bethesda

77030

MD Anderson Cancer Center, Houston

02114

Massachusetts General Hospital, Boston

02905

Women & Infants Hospital of Rhode Island, Providence